GSK Lotronex To Be Reviewed By FDA Drug Safety Cmte. In April
Executive Summary
FDA's Drug Safety & Risk Management Subcommittee will review the safety of GlaxoSmithKline's withdrawn irritable bowel syndrome agent Lotronex (alosetron) on April 23
You may also be interested in...
GSK Plans Lotronex Randomized Withdrawal Study If Drug Is Reintroduced
GlaxoSmithKline has committed to a randomized withdrawal study for Lotronex if the irritable bowel syndrome agent is allowed back onto the market
GSK Plans Lotronex Randomized Withdrawal Study If Drug Is Reintroduced
GlaxoSmithKline has committed to a randomized withdrawal study for Lotronex if the irritable bowel syndrome agent is allowed back onto the market
Rx Safety Cmte.’s Holmboe Sees Communication As Key To Risk Management
Yale University's Eric Holmboe, MD, will be taking his second look at risk-management proposals for GlaxoSmithKline's Lotronex during the inaugural meeting of FDA's Drug Safety & Risk Management Subcommittee